Cantor Fitzgerald Lifts PT on Eli Lilly and Company (LLY) on Q1 Earnings Call
Key takeaways
- In another development, Eli Lilly and Company (NYSE:LLY) announced on April 27 the signing of a definitive agreement for it to acquire Ajax.
- Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products.
- While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Cantor Fitzgerald Lifts PT on Eli Lilly and Company (LLY) on Q1 Earnings Call Noor Ul Ain Rehman Fri, May 8, 2026 at 12:26 AM GMT+7 2 min read LLY Eli Lilly and Company (NYSE:LLY) is one of the best strong buy stocks to invest in according to billionaires. Cantor Fitzgerald lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,230 from $1,205 on May 1, reaffirming an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 call highlighted solid OUS Mounjaro demand with potential upside to raised guidance and encouraging early Foundayo ramp commentary. It also cited improved earnings leverage supporting higher EPS expectations and multiple catalysts, including a potential 2H acceleration and anticipation of retatrutide, helping sustain engagement.
In another development, Eli Lilly and Company (NYSE:LLY) announced on April 27 the signing of a definitive agreement for it to acquire Ajax. Ajax is a biopharmaceutical company that develops next-generation JAK inhibitors for patients with myeloproliferative neoplasms, and its lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously been treated with a Type I JAK2 inhibitor.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.